Ambu A/S (OTCMKTS:AMBBY – Get Rating) was upgraded by stock analysts at DNB Markets from a "hold" rating to a "buy" rating in a research note issued to investors on Thursday, The Fly reports.
Separately, JPMorgan Chase & Co. increased their price target on Ambu A/S from 64.00 to 65.00 and gave the stock an "underweight" rating in a report on Wednesday, December 14th.
Get
Ambu A/S alerts:
Ambu A/S Price Performance
OTCMKTS:AMBBY opened at $14.55 on Thursday. The company has a 50 day simple moving average of $14.35 and a two-hundred day simple moving average of $11.99. Ambu A/S has a fifty-two week low of $8.08 and a fifty-two week high of $19.25.
About Ambu A/S
(Get Rating)
Ambu A/S engages in the development, production, and marketing of diagnostic and life-supporting devices for hospitals and rescue services. It operates through the following segments: Anaesthesia; Patient Monitoring & Diagnostics; and Visualisation. The Anaesthesia segment offers products from resuscitators, face masks, and laryngeal masks to the single use flexible intubation scope.
Recommended Stories
- Get a free copy of the StockNews.com research report on Ambu A/S (AMBBY)
- Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor
- Has Workhorse Group Finally Hit Bottom?
- Target Offering A Rare Buying Opportunity After Earnings
- Rivian Gives Investors a Taste of the Anxiety Its Consumers Feel
- 3 High-Yield Dividend Stocks That Are Probably Not On Your Radar
Receive News & Ratings for Ambu A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambu A/S and related companies with MarketBeat.com's FREE daily email newsletter.
AMBU A/S(OTCMKTS：AMBBY-GET RATING)據The Fly報道，在週四發佈給投資者的一份研究報告中，DNB Markets的股票分析師將其評級從持有上調至買入。
另外，摩根大通在12月14日週三的一份報告中將Ambu A/S的目標價從64.00上調至65.00，並給予該股“減持”評級。
到達
Ambu A/S警報：
Ambu A/S性價比
OTCMKTS：AMBBY週四開盤報14.55美元。該公司的50日簡單移動均線切入位在14.35美元，200日簡單移動均線切入位在11.99美元。Ambu A/S的52周低點為8.08美元，52周高點為19.25美元。
關於Ambu A/S
(獲取評級)
Ambu A/S致力於為醫院和救援服務開發、生產和銷售診斷和生命支持設備。它通過以下幾個部分運作：麻醉；病人監測和診斷；以及可視化。麻醉部分提供從復甦器、口罩和喉罩到一次性使用的靈活插管範圍的產品。
推薦故事
- 免費獲取StockNews.com關於Ambu A/S的研究報告(AMBBY)
- 華爾街認為肉毒桿菌競爭對手Revance的股價上漲23%
- 主力集團終於觸底了嗎？
- 目標產品盈利後難得的買入機會
- Rivian讓投資者感受到消費者的焦慮
- 3可能不在你的雷達上的高收益股利股票
接受Ambu A/S日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Ambu A/S和相關公司的最新新聞和分析師評級的每日簡要摘要。
